Lifecare said on social media that it completed a significant milestone in the development of its continuous glucose monitor (CGM) implant.
The Norway-based company says it completed the initial electromagnetic compatibility (EMC) testing of electronics developed for its next-generation CGM implant. EMC testing ensures that the implant can operate reliably when surrounded by mobile phones, Wi-Fi and other wireless technologies without interference or failure.
Results from the first round confirmed a stable technical foundation for the implant system. The company said in a LinkedIn post that it sets the company up to complete the final touches as it works toward CE mark approval. Lifecare expects full verification within three months with its final optimizations already underway.
In its LinkedIn post, Lifecare laid out a timeline for its CGM implant. It expects to begin first-in-human clinical trials this year, then submit for CE mark in 2026. If all goes according to plan, the company plans to launch the CGM implant commercially in 2027.
“This milestone brings us one step closer to offering people with diabetes a smarter, more convenient monitoring solution,” the company posted.
According to the Lifecare website, it develops miniaturized sensor technology that measures changes by reading osmotic pressure variations. The implantable CGM monitors changes in an osmotic pressure chamber, induced by changes in the interstitial fluid glucose concentrations in the subcutaneous tissue.
Implantable CGMs could rival the devices made by minimally invasive CGM leaders Dexcom and Abbott. Read more about Senseonics’ commercial CGM implant and Glucotrack’s long-term blood glucose monitor implant under development.
